SpecGX LLC, et al.; Withdrawal of Approval of 30 Abbreviated New Drug Applications

الملخص

The Food and Drug Administration (FDA or the Agency) is withdrawing approval of 30 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.